A novel, non-hallucinogenic, experimental drug shows statistically significant, rapid, and durable improvement in PTSD symptom severity in a phase 2 trial.

Analysts consider AtaiBeckley’s MDMA candidate a “high-risk, high-reward” bet after the drug demonstrated reductions in ...

"AtaiBeckley’s MDMA-based drug for anxiety shows benefit in Phase IIa trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Post-traumatic stress disorder (PTSD) is not only characterized by strongly encoded traumatic memories, but also by disrupted coordination across brain networks. New research shows that treatment with ...

Post-traumatic stress disorder (PTSD) is not only characterized by strongly encoded traumatic memories, but also by disrupted coordination across brain networks. New research shows that treatment with ...

I recount all this as someone who still remains very optimistic about psychedelics as medical treatments and tools of spiritual exploration.

The investigational neuroplastogen TSND-201 showed significant efficacy in patients with severe post-traumatic stress disorder (PTSD), according to results from a phase II randomized trial. Among 65 ...

For researcher Lynnette Averill, the quest to find a treatment for post-traumatic stress disorder (PTSD) is deeply personal. Averill's father served as an enlisted infantryman with the U.S. Marine ...

FOR FIVE years biotech startups have been betting that psychedelic substances could be turned into real medicines. One of them may have hit the jackpot. On February 17th Compass Pathways, a British ...

New experiments suggest a biological missing link that helps lock in the long-term benefits of psychedelic-assisted PTSD treatment ...

Ana Santos Rutschman does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations ...